PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
PharmAla Biotech Holdings Inc. (OTC:MDXXF) announced it has agreed to supply its LaNeo MDMA for a clinical trial at Harvard's Maclean Hospital, a world-leading institution in neuroscience and psychiatric research. This agreement marks a significant step for PharmAla as it continues to expand its role in supporting MDMA-based clinical research across the U.S. The company's CEO, Nicholas Kadysh, emphasized the growing interest from key research organizations and the company's commitment to delivering high-quality MDMA for clinical trials. This development comes less than a month after PharmAla was contracted to be a supplier of MDMA to a clinical trial at Johns Hopkins Medicine.
PharmAla生物科技控股公司（場外交易:MDXXF）宣佈已同意爲哈佛麥克林醫院的臨床試驗提供其LaNeo MDMA，該醫院是全球領先的神經科學和精神研究機構。這一協議標誌着PharmAla在繼續支持全美範圍內基於MDMA的臨床研究的角色擴大的重要一步。公司首席執行官尼古拉斯·卡迪什強調了來自關鍵研究機構的日益增長的興趣，以及公司致力於爲臨床試驗提供高質量MDMA的承諾。此項進展發生在PharmAla被約翰霍普金斯醫學院合同聘爲一項臨床試驗的MDMA供應商不到一個月之後。
Additionally, PharmAla will be attending the CPHI conference in Milan from October 7-11, where the company aims to further discussions with potential European distribution partners. Dr. Shane Morris, COO of PharmAla, highlighted the ongoing efforts to expand their distribution network in Europe. "Over the past few months, PharmAla has been in discussion with a number of potential distribution partners in the European market," he said. "We're looking forward to the opportunity to meet with them, in-person, to continue those fruitful discussions."
此外，PharmAla將參加於10月7日至11日在米蘭舉辦的CPHI會議，公司旨在進一步與潛在的歐洲分銷合作伙伴進行討論。PharmAla的首席運營官沙恩·莫里斯博士強調了擴大他們在歐洲的分銷網絡的不懈努力。"在過去幾個月裏，PharmAla一直在與歐洲市場上的許多潛在分銷夥伴進行討論，"他說。"我們期待着與他們當面會晤，繼續那些富有成效的討論。"
Cover image made wth AI
封面圖片是用人工智能製作的
譯文內容由第三人軟體翻譯。